Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate
The present invention relates to a process for the preparation of crystalline Form I of methanesulfonate salt of dabigatran etexilate. (Formula (I)). The present invention does not require the isolation of the dabigatran etexilate intermediate.
1. A process for the preparation of crystalline Form I of a methanesulfonate salt of dabigatran etexilate, wherein the process comprises
a) contacting ethyl N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-3a,7a-dihydro-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-β-alaninate of Formula IV
or salts thereof with n-hexyl chloroformate;
b) treating the reaction mixture obtained in step a) with methane sulfonic acid; and
c) isolating the crystalline Form I of the methanesulfonate salt of dabigatran etexilate from the mixture thereof.
2. The process according to claim 1 , wherein the salt of the compound Formula IV is selected from hydrochloride, hydrobromide, or acetate salts.
3. The process according to claim 2 , wherein the salt of the compound of Formula IV is an acetate salt.
4. The process according to claim 1 , wherein the compound of Formula IV is contacted with n-hexyl chloroformate in the presence of a solvent selected from the group consisting of water, ethers, halogenated hydrocarbons, esters, or mixtures thereof.
5. The process according to claim 4 , wherein the solvent is tetrahydrofuran, or tetrahydrofuran in combination with water.
6. The process according to claim 1 , wherein n-hexyl chloroformate is used either as a solid or in a solution with tetrahydrofuran.
7. The process according to claim 1 , wherein the compound of Formula IV is contacted with n-hexyl chloroformate in the presence of a base.
8. The process according to claim 7 , wherein the base is potassium carbonate.
9. The process according to claim 1 , wherein the product prepared in step a) is not isolated.
10. The process according to claim 1 , wherein the reaction mixture obtained in step a) is treated with methane sulfonic acid in a solvent selected from the group consisting of ketones, esters, alcohols, or mixtures thereof.
11. The process according to claim 10 , wherein the solvent is acetone.
12. The process according to claim 1 , wherein methane sulfonic acid is used as a solid or in solution with acetone.
13. The process according to claim 1 , wherein the crystalline Form I of the methanesulfonate salt of dabigatran etexilate has substantially the same XRPD pattern as depicted in FIG. 1 .